Advanced

Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.

Berntorp, Erik LU (2009) In Haemophilia 15. p.41343-41343
Abstract
Summary. The bypassing agents factor eight inhibitor bypassing activity (FEIBA) anti-inhibitor coagulant complex and recombinant activated factor VII (rFVIIa) have been established as safe and effective therapies for treating bleeding episodes in haemophilia patients with inhibitors. However, the efficacy of each bypassing agent can vary, and neither agent is universally effective. The reasons for such variability have yet to be confirmed, but may involve patient-specific factors and the mechanisms of action (MOAs) and pharmacokinetic profiles of these two agents. This issue underscores the necessity of both products in the comprehensive care of patients with haemophilia and inhibitors. The objective of this review is to discuss the... (More)
Summary. The bypassing agents factor eight inhibitor bypassing activity (FEIBA) anti-inhibitor coagulant complex and recombinant activated factor VII (rFVIIa) have been established as safe and effective therapies for treating bleeding episodes in haemophilia patients with inhibitors. However, the efficacy of each bypassing agent can vary, and neither agent is universally effective. The reasons for such variability have yet to be confirmed, but may involve patient-specific factors and the mechanisms of action (MOAs) and pharmacokinetic profiles of these two agents. This issue underscores the necessity of both products in the comprehensive care of patients with haemophilia and inhibitors. The objective of this review is to discuss the evidence of a differential haemostatic response to bypassing agents and the potential roles of MOA and patient-specific factors in contributing to the differences in response. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Haemophilia
volume
15
pages
41343 - 41343
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • wos:000262470600002
  • pmid:19016901
  • scopus:63049090494
ISSN
1351-8216
DOI
10.1111/j.1365-2516.2008.01931.x
language
English
LU publication?
yes
id
226c587f-8a14-49d9-84c5-89248fda581e (old id 1271370)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19016901?dopt=Abstract
date added to LUP
2008-12-03 11:13:31
date last changed
2017-11-19 04:19:26
@article{226c587f-8a14-49d9-84c5-89248fda581e,
  abstract     = {Summary. The bypassing agents factor eight inhibitor bypassing activity (FEIBA) anti-inhibitor coagulant complex and recombinant activated factor VII (rFVIIa) have been established as safe and effective therapies for treating bleeding episodes in haemophilia patients with inhibitors. However, the efficacy of each bypassing agent can vary, and neither agent is universally effective. The reasons for such variability have yet to be confirmed, but may involve patient-specific factors and the mechanisms of action (MOAs) and pharmacokinetic profiles of these two agents. This issue underscores the necessity of both products in the comprehensive care of patients with haemophilia and inhibitors. The objective of this review is to discuss the evidence of a differential haemostatic response to bypassing agents and the potential roles of MOA and patient-specific factors in contributing to the differences in response.},
  author       = {Berntorp, Erik},
  issn         = {1351-8216},
  language     = {eng},
  pages        = {41343--41343},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {Haemophilia},
  title        = {Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.},
  url          = {http://dx.doi.org/10.1111/j.1365-2516.2008.01931.x},
  volume       = {15},
  year         = {2009},
}